• Hims & Hers Health (NYSE:HIMS) has agreed to acquire Australian digital health company Eucalyptus, advancing its international expansion beyond the U.S.
• The deal gives Hims & Hers immediate access to new markets through Eucalyptus’s existing telehealth brands and infrastructure.
• This move comes as attention has recently centered on the company’s partnerships and legal developments around weight loss treatments.

Hims & Hers Health, trading at $24.77, has seen sharp share price swings recently, with a 57.4% gain over the past week and a 48.4% gain over the past month. Over longer periods, returns are mixed, with a 25.9% decline year to date and a 25.3% decline over the past year, alongside a very large 3-year gain and a 71.4% return over 5 years. For investors, the Eucalyptus acquisition comes on top of this volatile share performance and adds a new angle to the story.

The company has been vocal about its aim to build a broad consumer health platform, and Eucalyptus gives it a ready-made presence in non-U.S. markets. As Hims & Hers integrates these assets and expands its service mix, investors may watch how execution, regulatory conditions, and customer adoption in new regions shape the risk and opportunity profile for NYSE:HIMS.

Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health.

Quick Assessment

• ⚖️ Price vs Analyst Target: At $24.77, Hims & Hers Health trades about 7% above the $23.12 analyst consensus target.
• ✅ Simply Wall St Valuation: The shares are flagged as trading roughly 57.5% below Simply Wall St's estimated fair value.
• ✅ Recent Momentum: The stock has returned about 48.4% over the past 30 days.

There is only one way to know the right time to buy, sell or hold Hims & Hers Health. Head to the Simply Wall St company report for the latest analysis of Hims & Hers Health's Fair Value.

Key Considerations

• 📊 The Eucalyptus deal extends Hims & Hers Health beyond the U.S., so your thesis may now hinge more on global execution rather than a purely domestic story.
• 📊 Keep an eye on integration costs, the P/E of 43.98 versus the Healthcare industry average of about 22.15, and whether international revenue starts to meaningfully contribute.
• ⚠️ Current minor risk flags include volatile recent share price moves and a high level of debt, which can matter more when a company is expanding into new markets.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Hims & Hers Health analysis. Alternatively, you can visit the community page for Hims & Hers Health to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.